eTable 1 Effect of treatment allocation on All-cause mortality and CVD-mortality reported within trial period

Study	Difference in proportion taking statins within-trial (%)[1]	Allocated to statins			Allocated to placebo			Risk Estimates	
		N	All deaths	CVD deaths	N	All deaths	CVD deaths	All deaths	CVD deaths
ALLHAT-LLT	79	5089	661	529	5110	678	546	0.97 (0.87-1.07)[2]	0.96 (0.83-1.13)[2]
ASCOT-LLA	78	5168	460	154	5137	520	167	0.87 (0.71-1.06)[2]	0.90 (0.66-1.23)[2]
WOS-COPS	70	3302	106	49	3293	135	71	**0.76 (0.59-0.98)[2]**	**0.66 (0.46-0.95)[2]**
ALERT	71	1050	143	66	1052	138	73	1.02 (0.81-1.30)[3]	**0.62 (0.40-0.96)[3]**
SSSS	88	2221	182	136	2223	256	207	**0.70 (0.58-0.84)[3]**	**0.64 (0.52-0.80)[3]**
PROSPER	89	2891	298	122	2913	306	154	0.97 (0.83–1.14)[2]	**0.77 (0.61–0.98)[2]**
HPS	68	10269	1328	826	10267	1507	998	**0.87(0.81-0.94)[3]**	**0.82 (0.75-0.90)[3]**
LIPID	57	4512	498	331	4502	633	433	**0.77 (0.69-0.87)[3]**	**0.75 (0.65-0.87)[3]**

Notes

1. Difference in % taking statins = [% taking statins in group allocated to statin in trial - % taking statins in group allocated to placebo in trial]
2. Studies reporting Hazard Ratio
3. Studies reporting Relative Risk

4. Statistically significant results are **bolded**
5. CVD = Cardiovascular Disease
6. Order of trials within primary prevention and secondary prevention is from shortest post-trial follow-up to longest.

eTable 2 Effect of treatment allocation on All-cause mortality and CVD-mortality reported for post-trial period

Study	Average post-trial follow-up	Difference in proportion taking statins post-trial (%)[1]	Allocated to statins			Allocated to placebo			Risk Ratio	
			N^4	All deaths	CVD deaths	N^4	All deaths	CVD deaths	All deaths	CVD deaths
ALLHAT-LLT	4	?	4428	897	484	4432	948	511	0.91 (0.79–1.04)[2]	0.95 (0.87-1.05)[2]
ASCOT-LLA	8.3	4	2234	377	124	2198	430	131	**0.85 (0.74-0.98)**[2]	0.91 (0.71-1.16)[2]
WOS-COPS	15.1	4	3196	1036	364	3158	1117	423	**0.88 (0.81-0.96)**[2]	**0.82 (0.71-0.94)**[2]
ALERT	1.6	0	811	51	22	820	51	25	1.01 (0.69 - 1.47)[3]	0.89 (0.51 - 1.56)[3]
SSSS	5	4	2039	232	155	1967	212	128	1.03 (0.86-1.24)[3]	1.14 (0.90-1.44)[3]
PROSPER	5.4	?	2588	931	396	2600	928	375	0.99 (0.91-1.09)[2]	1.03 (0.89-1.18)[2]
HPS	5.7	0	8863	1962	1019	8656	1949	1007	0.98 (0.90-1.07)[3]	0.98 (0.92-1.04)[3]
LIPID	10	1	3932	1341	756	3789	1319	765	0.97 (0.90-1.05)[3]	0.94 (0.85-1.04)[3]

Notes

1. Difference in % taking statins = [% taking statins in group allocated to statin in trial - % taking statins in group allocated to placebo in trial]
2. Studies reporting Hazard Ratio
3. Studies reporting Relative Risk
4. Number alive and followed post-trial
5. Statistically significant results are **bolded**

6. CVD = Cardiovascular Disease
7. Order of trials within primary prevention and secondary prevention is from shortest post-trial follow-up to longest